Latest Endo Pharmaceuticals Stories
CHADDS FORD, Pa., Aug. 25, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that Blaine Davis, vice president corporate affairs will present a corporate overview at the Stifel Nicolaus Annual Healthcare Conference on Thursday, September 8, 2011 at 11:30 a.m. ET. The conference will be held at the Four Seasons Hotel in Boston, MA. A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/. Click on...
CHADDS FORD, Pa., Aug. 22, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today the appointment of Kelly Huang, Ph.D., to the position of President, HealthTronics Inc., effective Aug. 29, 2011. HealthTronics, an Endo subsidiary, is a leading U.S. provider of urological products and services based in Austin, Texas. Huang will take over leadership from current HealthTronics Group President James Whittenburg, who is staying through the remainder of the year to effect a...
CHADDS FORD, Pa., Aug. 17, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it is terminating its research program and collaboration related to the development of axomadol. Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009. "As a leader in the field of pain management, Endo remains committed to the development and commercialization of pain therapeutics," said Ivan Gergel, M.D.,...
EAST NORRITON, Pa., Aug. 15, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today announced that it has appointed Diane Jorkasky, M.D., who recently joined Endo Pharmaceuticals (Nasdaq: ENDP) as Senior Vice President, Clinical Development and Chief Medical Officer, to its Board of Directors. Tengion also announced today that Brenda Gavin, D.V.M., Managing Partner at Quaker BioVentures, is stepping down from the Tengion Board of Directors after five years of service. Quaker BioVentures...
CHADDS FORD, Pa., Aug. 9, 2011 /PRNewswire/ -- Total quarterly revenues of $608 million increase 53 percent versus prior year; Reported quarterly diluted EPS of $0.44 versus $0.44 for prior year;Adjusted diluted EPS of $1.05 reflecting growth of 30 percent from 2010;Company increases 2011 revenue guidance to a range of $2.72 to $2.80 billion; andCompany increases 2011 adjusted diluted EPS guidance to a range of $4.55 to $4.65 and Reported or GAAP diluted EPS to a range $2.22 to $2.32...
CHADDS FORD, Pa., July 26, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will host a conference call and live Internet webcast on Tuesday, August 9, 2011 at 8:30 a.m. ET to discuss results for the 2011 second quarter. David P. Holveck, president and CEO, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, Tony Bihl, group president, American Medical...
Strengthens Management Team Record Quarterly Pennsaid Prescriptions MISSISSAUGA, ON, July 20, 2011 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, announced today that it has appointed Eric Vandal as Vice President of Sales and Marketing and Arnold Gammaitoni, Pharm.D., as Vice President of Scientific Affairs in its Pain Group. Both Mr. Vandal and Dr. Gammaitoni...
MISSISSAUGA, ON, July 5, 2011 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that its Marketing Authorization Application (MAA) for Pliaglis has been validated in the European Union (EU). The MAA was submitted using the decentralized procedure to request marketing approval for Pliaglis for the indication of producing local dermal anaesthesia on intact...
CHADDS FORD, Pa., June 30, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study end points. The company is currently completing additional analyses of the data and evaluating the path forward for the program. The study was a...
RALEIGH, N.C., June 27, 2011 /PRNewswire/ -- Curaxis Pharmaceutical Corporation (OTCQB: CURX) ("Curaxis" or the "Company") today announced that it has replaced the Company's Board of Directors (the "Board") and the executive management team to better position the Company for its next phase of growth and development. Joining the Board will be Timothy Wright, Terence Novak, Michael George, Michael Miller, Ivan Gothner and Stephen Leary. Dr. Bert Spilker, who is a current Board member, will...
